Stocktoria
Lunai Bioworks Inc. LNAI
Lunai Bioworks Inc. (LNAI) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2026 revenue was $51,992 at a -6852.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 2081 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| LNAI | Lunai Bioworks Inc. | 2/9 | — | — | — |
| HCWB | HCW Biologics Inc. | 2/9 | — | — | — |
| AVTX | Avalo Therapeutics, Inc. | 1/9 | -8.95 | — | — |
| ALT | Altimmune, Inc. | 4/9 | 0.63 | — | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | 1/9 | — | — | — |
| CNTB | Connect Biopharma Holdings Ltd | 1/9 | — | — | -99.8% |
| AXIM | AXIM BIOTECHNOLOGIES, INC. | 3/9 | — | — | — |
About Lunai Bioworks Inc.
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.
FAQ
Is LNAI financially healthy?
Lunai Bioworks Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does LNAI pay a dividend?
No, Lunai Bioworks Inc. does not currently pay a dividend.
How profitable is LNAI?
In FY2026, Lunai Bioworks Inc. had a net margin of -6852.0%.
Is LNAI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Lunai Bioworks Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-06-30. Facts plus Stocktoria's own computed scores — not investment advice.